| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 295.48% | Baird | → $7 | Initiates Coverage On | → Outperform |
| 04/27/2022 | — | Evercore ISI Group | Initiates Coverage On | → In-Line | |
| 12/07/2021 | 916.95% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 12/06/2021 | 1086.44% | B of A Securities | → $21 | Initiates Coverage On | → Buy |
What is the target price for Vaxxinity (VAXX)?
The latest price target for Vaxxinity (NASDAQ: VAXX) was reported by Baird on September 8, 2023. The analyst firm set a price target for $7.00 expecting VAXX to rise to within 12 months (a possible 295.48% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vaxxinity (VAXX)?
The latest analyst rating for Vaxxinity (NASDAQ: VAXX) was provided by Baird, and Vaxxinity initiated their outperform rating.
When is the next analyst rating going to be posted or updated for Vaxxinity (VAXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaxxinity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaxxinity was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
Is the Analyst Rating Vaxxinity (VAXX) correct?
While ratings are subjective and will change, the latest Vaxxinity (VAXX) rating was a initiated with a price target of $0.00 to $7.00. The current price Vaxxinity (VAXX) is trading at is $1.77, which is within the analyst's predicted range.